Skip to content

Ceredex Value Advisors LLC: META position timeline

Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Ceredex Value Advisors LLC on META, newest first. How the timeline and the estimate are built.

Ceredex Value Advisors LLC held 31,576 META shares at 2026-06-30 per its 13F-HR filed 2026-08-11.

the latest 13F is the newest step

  1. period ended2026-06-30
    13F 31,576 shares
    Change vs previous 13F +3,355 shares

    0.5% of the 13F portfolio, value $17,786,445.

    13F-HR 0001738726-26-000006 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  2. period ended2026-03-31
    13F 28,221 shares
    Change vs previous 13F -4,581 shares

    0.51% of the 13F portfolio, value $16,146,081.

    13F-HR 0001738726-26-000004 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  3. period ended2025-12-31
    13F 32,802 shares
    Change vs previous 13F -14,397 shares

    0.65% of the 13F portfolio, value $21,652,272.

    13F-HR 0001738726-26-000002 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  4. period ended2025-09-30
    13F/A 47,199 shares
    Change vs previous 13F -12,604 shares

    0.8% of the 13F portfolio, value $34,662,002.

    13F-HR/A 0001628280-25-052325 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).

  5. period ended2025-06-30
    13F 59,803 shares
    Change vs previous 13F not available

    0.95% of the 13F portfolio, value $44,139,997.

    13F-HR 0001587281-25-000003 filed by Ceredex Value Advisors LLC
    Filed (acceptance time not in the bulk data set), ingested

    Acceptance time not in the bulk data set (spec §4.2).